- Home
- AKTX vs SCNX Comparison
AKTX vs SCNX Comparison
Compare AKTX & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- SCNX
- Stock Information
- Founded
- AKTX N/A
- SCNX 2010
- Country
- AKTX United States
- SCNX United States
- Employees
- AKTX N/A
- SCNX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- AKTX Health Care
- SCNX Health Care
- Exchange
- AKTX Nasdaq
- SCNX Nasdaq
- Market Cap
- AKTX 35.7M
- SCNX 21.2M
- IPO Year
- AKTX N/A
- SCNX 2020
- Fundamental
- Price
- AKTX $1.08
- SCNX $1.71
- Analyst Decision
- AKTX
- SCNX
- Analyst Count
- AKTX 0
- SCNX 0
- Target Price
- AKTX N/A
- SCNX N/A
- AVG Volume (30 Days)
- AKTX 22.7K
- SCNX 202.2K
- Earning Date
- AKTX 08-18-2025
- SCNX 08-10-2025
- Dividend Yield
- AKTX N/A
- SCNX N/A
- EPS Growth
- AKTX N/A
- SCNX N/A
- EPS
- AKTX N/A
- SCNX N/A
- Revenue
- AKTX N/A
- SCNX $146,901.00
- Revenue This Year
- AKTX N/A
- SCNX N/A
- Revenue Next Year
- AKTX N/A
- SCNX N/A
- P/E Ratio
- AKTX N/A
- SCNX N/A
- Revenue Growth
- AKTX N/A
- SCNX N/A
- 52 Week Low
- AKTX $0.85
- SCNX $0.69
- 52 Week High
- AKTX $4.40
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- AKTX 41.09
- SCNX N/A
- Support Level
- AKTX $1.10
- SCNX N/A
- Resistance Level
- AKTX $1.15
- SCNX N/A
- Average True Range (ATR)
- AKTX 0.03
- SCNX 0.00
- MACD
- AKTX 0.00
- SCNX 0.00
- Stochastic Oscillator
- AKTX 10.00
- SCNX 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.